Radiolabelled aptamers for theranostic treatment of cancer

Khalid, Umair, Vi, Chris, Henri, Justin Liam, Macdonald, Joanna, Eu, Peter, Mandarano, Giovanni and Shigdar, Sarah 2019, Radiolabelled aptamers for theranostic treatment of cancer, Pharmaceuticals, vol. 12, no. 1, doi: 10.3390/ph12010002.

Attached Files
Name Description MIMEType Size Downloads

Title Radiolabelled aptamers for theranostic treatment of cancer
Author(s) Khalid, Umair
Vi, Chris
Henri, Justin Liam
Macdonald, Joanna
Eu, Peter
Mandarano, GiovanniORCID iD for Mandarano, Giovanni orcid.org/0000-0002-8689-4070
Shigdar, SarahORCID iD for Shigdar, Sarah orcid.org/0000-0001-8084-8447
Journal name Pharmaceuticals
Volume number 12
Issue number 1
Article ID 2
Total pages 20
Publisher MDPI
Place of publication Basel, Switzerland
Publication date 2019
ISSN 1424-8247
Keyword(s) EpCAM
aptamers
cancer
chelating agents
diagnostics
molecular imaging
radiolabel
targeted imaging
theranostics
therapeutics
Summary Cancer has a high incidence and mortality rate worldwide, which continues to grow as millions of people are diagnosed annually. Metastatic disease caused by cancer is largely responsible for the mortality rates, thus early detection of metastatic tumours can improve prognosis. However, a large number of patients will also present with micrometastasis tumours which are often missed, as conventional medical imaging modalities are unable to detect micrometastases due to the lack of specificity and sensitivity. Recent advances in radiochemistry and the development of nucleic acid based targeting molecules, have led to the development of novel agents for use in cancer diagnostics. Monoclonal antibodies may also be used, however, they have inherent issues, such as toxicity, cost, unspecified binding and their clinical use can be controversial. Aptamers are a class of single-stranded RNA or DNA ligands with high specificity, binding affinity and selectivity for a target, which makes them promising for molecular biomarker imaging. Aptamers are presented as being a superior choice over antibodies because of high binding affinity and pH stability, amongst other factors. A number of aptamers directed to cancer cell markers (breast, lung, colon, glioblastoma, melanoma) have been radiolabelled and characterised to date. Further work is ongoing to develop these for clinical applications.
Language eng
DOI 10.3390/ph12010002
Field of Research 1115 Pharmacology and Pharmaceutical Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018, The Authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30117343

Document type: Journal Article
Collections: School of Medicine
Open Access Checking
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 0 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 31 Jan 2019, 10:10:21 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.